The Effects of TMZ on Diabetic Nephropathy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.

Also called NCT05147194

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05147194
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05147194. Randomized; no masking; primary purpose treatment. Start 2022-01-01 (anticipated); primary completion 2023-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effects of TMZ on Diabetic Nephropathy
Condition
Diabetic Nephropathies
Intervention (Drug)
Trimetazidine
Lead sponsor
Tongji Hospital (class: other)

Record details

Record id
cardio:ct-nct05147194
Content hash
122a61050e84b5855337466c830184b7ae6a7329b60683eab8f5d482a390a451